U.S. markets closed
  • S&P Futures

    4,360.50
    -43.25 (-0.98%)
     
  • Dow Futures

    34,002.00
    -251.00 (-0.73%)
     
  • Nasdaq Futures

    14,318.50
    -182.50 (-1.26%)
     
  • Russell 2000 Futures

    2,007.90
    -23.80 (-1.17%)
     
  • Crude Oil

    83.64
    +0.33 (+0.40%)
     
  • Gold

    1,842.50
    +0.80 (+0.04%)
     
  • Silver

    23.84
    +0.05 (+0.19%)
     
  • EUR/USD

    1.1325
    -0.0005 (-0.05%)
     
  • 10-Yr Bond

    1.7350
    -0.0120 (-0.69%)
     
  • Vix

    29.90
    +1.05 (+3.64%)
     
  • GBP/USD

    1.3481
    -0.0009 (-0.07%)
     
  • USD/JPY

    113.9060
    -0.0540 (-0.05%)
     
  • BTC-USD

    36,087.52
    +109.62 (+0.30%)
     
  • CMC Crypto 200

    821.53
    +10.93 (+1.35%)
     
  • FTSE 100

    7,297.15
    -196.98 (-2.63%)
     
  • Nikkei 225

    27,113.13
    -475.24 (-1.72%)
     

Green Thumb Industries Inc. (CSE:GTII) Is Expected To Breakeven

  • Oops!
    Something went wrong.
    Please try again later.
·3 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • GTII

Green Thumb Industries Inc.'s (CSE:GTII): Green Thumb Industries Inc. manufactures, distributes, markets, and sells various cannabis consumer packaged goods for medical and adult use in the United States. The CA$2.0b market-cap company announced a latest loss of -US$59.1m on 31 December 2019 for its most recent financial year result. The most pressing concern for investors is GTII’s path to profitability – when will it breakeven? Below I will provide a high-level summary of the industry analysts’ expectations for GTII.

See our latest analysis for Green Thumb Industries

According to the 17 industry analysts covering GTII, the consensus is breakeven is near. They expect the company to post a final loss in 2020, before turning a profit of US$47m in 2021. Therefore, GTII is expected to breakeven roughly a few months from now. In order to meet this breakeven date, I calculated the rate at which GTII must grow year-on-year. It turns out an average annual growth rate of 69% is expected, which is extremely buoyant. If this rate turns out to be too aggressive, GTII may become profitable much later than analysts predict.

CNSX:GTII Past and Future Earnings May 5th 2020
CNSX:GTII Past and Future Earnings May 5th 2020

Underlying developments driving GTII’s growth isn’t the focus of this broad overview, however, keep in mind that by and large a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in. This means that a high growth rate is not unusual, especially if the company is currently in an investment period.

Before I wrap up, there’s one aspect worth mentioning. GTII has managed its capital judiciously, with debt making up 11% of equity. This means that GTII has predominantly funded its operations from equity capital,and its low debt obligation reduces the risk around investing in the loss-making company.

Next Steps:

This article is not intended to be a comprehensive analysis on GTII, so if you are interested in understanding the company at a deeper level, take a look at GTII’s company page on Simply Wall St. I’ve also put together a list of key aspects you should look at:

  1. Valuation: What is GTII worth today? Has the future growth potential already been factored into the price? The intrinsic value infographic in our free research report helps visualize whether GTII is currently mispriced by the market.

  2. Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Green Thumb Industries’s board and the CEO’s back ground.

  3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.